Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00501046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableResults first posted: Mar 2, 2015Primary endpoints revised (2) · Secondary endpoints revised (2) · Publications: 2 to 3v13Show 3 more changesShow less
NotablePrimary endpoints: 1 to 2Study sites: 28 to 38 · Primary and study completion dates: Jan 2011 · Interventions: AST-120 (Drug) to AST-120 (Drug), Placebo (Drug) · 3 morev3Show 6 more changesShow less
Study sites: 28 to 38
Primary and study completion dates: Jan 2011
Interventions: AST-120 (Drug) to AST-120 (Drug), Placebo (Drug)
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 28 · Start date: Jul 2007v2Show 2 more changesShow less
Study sites: 0 to 28
Start date: Jul 2007
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate the effects of AST-120 versus placebo, on other measures of renal function and quality of life.